Sydney, 16 February 2012 – Bayer Pharma AG and Bayer Australia Limited instituted Federal Court proceedings yesterday against Lupin Australia Pty Limited and Generic Health Pty Ltd alleging infringement of the Bayer Australian Patent No. 780330 (pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive) covering Yasmin® and Yaz®.
Bayer has alleged infringement and sought permanent injunctions to restrain Generic Health and Lupin from importing, marketing and selling their oral contraceptive Isabelle, together with damages or an account of profits.
Bayer Australia General Counsel Emma Press said the company had established patent rights to protect its considerable investment in the research and development necessary to bring its unique Yasmin® and Yaz® products to Australian consumers.
“Bayer is determined to enforce these patent rights and is committed to doing so as quickly as possible,” Emma Press said.
The case is listed for a first hearing on 19 March.